Sherbrooke Park Advisers LLC Acquires 6,117 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Sherbrooke Park Advisers LLC boosted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 43.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 20,066 shares of the biotechnology company’s stock after acquiring an additional 6,117 shares during the period. Sherbrooke Park Advisers LLC’s holdings in ADMA Biologics were worth $344,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics in the 4th quarter valued at about $35,000. Vision Financial Markets LLC bought a new stake in ADMA Biologics in the 4th quarter valued at about $51,000. AlphaQuest LLC bought a new stake in ADMA Biologics in the 4th quarter valued at about $84,000. CIBC Private Wealth Group LLC raised its stake in ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 2,954 shares during the period. Finally, Jones Financial Companies Lllp raised its stake in ADMA Biologics by 303.4% in the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 4,312 shares during the period. 75.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the topic of a number of research reports. Raymond James boosted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research note on Thursday, May 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. Finally, StockNews.com lowered ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ADMA Biologics presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Stock Up 2.6%

ADMA stock opened at $19.69 on Monday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $4.70 billion, a PE ratio of 70.32 and a beta of 0.57. ADMA Biologics, Inc. has a twelve month low of $9.22 and a twelve month high of $25.67. The stock has a 50-day simple moving average of $20.49 and a two-hundred day simple moving average of $18.86.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $114.80 million for the quarter, compared to analysts’ expectations of $116.40 million. During the same period in the previous year, the firm posted $0.08 EPS. The firm’s revenue for the quarter was up 40.2% compared to the same quarter last year. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.